<DOC>
	<DOCNO>NCT00030966</DOCNO>
	<brief_summary>The purpose study determine natalizumab combination AVONEX safe effective delay progression individual diagnose relapse remit Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>Safety Efficacy Natalizumab Combination With Avonex Treatment Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosis MS define McDonald et al , criterion , # 1 4 Between age 18 55 , inclusive Baseline EDSS score 0.0 5.0 , inclusive Have treat Avonex least 12 month prior randomization Have experience least one relapse ( Avonex ) within 12 month prior randomization . Cranial MRI scan demonstrating lesion consistent MS. Have give write informed consent participate study . Primary progressive , secondary progressive , progressive relapse MS. MS relapse occur within 50 day randomization A clinically significant infectious illness within 30 day prior randomization History , abnormal lab result , indicative significant disease , opinion investigator , would preclude administration recombinant humanize antibody immunomodulating agent Avonex 116 week . History severe allergic anaphylactic reaction know drug hypersensitivity . Unable perform Timed 25Foot Walk , 9HPT PASAT 3 Abnormal blood test Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>